Vaccine start-up scores $300m valuation from venture capitalists
MELBOURNE: An Australian start-up developing a vaccine against one of the world’s most prolific bacterial
MELBOURNE: An Australian start-up developing a vaccine against one of the world’s most prolific bacterial